Possis to start cerebrovascular stroke trial:
This article was originally published in Clinica
Possis Medical has received approval from the FDA to begin US clinical trials of its clot-busting AngioJet system in the treatment of severe acute cerebrovascular stroke. The Phase I trial will enrol 30 patients at six hospitals, said the Minneapolis, Minnesota-based company. The AngioJet device is already approved in the US for removing blood clots in coronary arteries and bypass grafts and is currently being assessed as a treatment for carotid stroke (see Clinica No 844, p 16).
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.